1. Home
  2. AOUT vs ENGN Comparison

AOUT vs ENGN Comparison

Compare AOUT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Outdoor Brands Inc.

AOUT

American Outdoor Brands Inc.

HOLD

Current Price

$9.76

Market Cap

121.7M

Sector

Industrials

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$1.64

Market Cap

115.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AOUT
ENGN
Founded
2020
1999
Country
United States
Canada
Employees
N/A
82
Industry
Ordnance And Accessories
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
121.7M
115.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
AOUT
ENGN
Price
$9.76
$1.64
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$12.50
$21.08
AVG Volume (30 Days)
32.1K
3.6M
Earning Date
03-12-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
98.94
N/A
EPS
N/A
N/A
Revenue
$222,322,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.55
N/A
52 Week Low
$6.26
$1.40
52 Week High
$13.46
$12.25

Technical Indicators

Market Signals
Indicator
AOUT
ENGN
Relative Strength Index (RSI) 52.29 29.13
Support Level $8.09 $1.40
Resistance Level $9.84 $1.87
Average True Range (ATR) 0.50 0.11
MACD 0.02 0.20
Stochastic Oscillator 63.24 37.84

Price Performance

Historical Comparison
AOUT
ENGN

About AOUT American Outdoor Brands Inc.

American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: